Product Name:

NebuPeptide™ Leuprorelin (Peptide Reference)

Catalog Number:

NBS-233773

Description:

NebuPeptide™ Leuprorelin (Peptide Reference)(CAT#NBS-233773) is synthesized in accordance with the Leuprorelin sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Insulin Detemir reference peptide ranging from milligrams to kilograms.

Peptide Name:

Leuprorelin

Background:

Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy. It is given by injection into a muscle or under the skin. Leuprorelin is in the gonadotropin-releasing hormone (GnRH) analogue family of medications. It works by decreasing gonadotropins and therefore decreasing testosterone and estradiol. Leuprorelin was patented in 1973 and approved for medical use in the United States in 1985.

Alias:

NSC-377526; NSC 377526; Leuprorelin; A-43818; A 43818; A43818; NSC377526; leuprolide acetate; Leuprorelinum Eligard

CAS Number:

53714-56-0

Formula:

C59H84N16O12

Molecular Weight:

1209.42

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.